Pagibaximab Biosimilar - Research Grade

Human

Staphylococcus epidermidis lipoteichoic acid [Staphylococcus epidermidis]

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

Staphylococcus epidermidis lipoteichoic acid is a conserved cell-wall component studied in anti-staphylococcal and biofilm research. This recombinant human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of pagibaximab, expressed in CHO cells against this antigen. For research use only, it is prepared to low endotoxin for in vivo suitability and produced in scalable milligram (mg) to gram (g) quantities for high-throughput laboratories. It functions as a defined reagent for functional binding and opsonization assays, antibody-mediated clearance studies, and preclinical models of staphylococcal infection. It delivers the consistency that bulk-consuming research programs require.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks